In an effort to support global initiatives to contain the spread of the new coronavirus (COVID-19), the Academy is presenting Spring 2020 events through online platforms and some of our previously scheduled events are being postponed to a later date. Please check our events listing for the latest information and contact our Customer Service team with any additional questions. For Academy programs and resources about COVID-19, click here.

We are experiencing intermittent technical difficulties. At this time, you may not be able to log in, register for an event, or make a donation via the website. We appreciate your patience, and apologize for any inconvenience this may cause.

This site uses cookies.
Learn more.


This website uses cookies. Some of the cookies we use are essential for parts of the website to operate while others offer you a better browsing experience. You give us your permission to use cookies, by continuing to use our website after you have received the cookie notification. To find out more about cookies on this website and how to change your cookie settings, see our Privacy policy and Terms of Use.


Annals Reports (7)

Edited by Edited by Annals of the New York Academy of Sciences editorial staff
Annals Reports (7)

Published: April 2014

Volume 1313

Learn More

This volume presents a report that maps out a course of action in four key priority areas for successfully developing effective treatments for Alzheimer's disease (AD). These areas include (1) addressing the fundamental mechanisms of disease, with the goal of developing a core set of research tools, a framework for data sharing, and creation of accessible validated and replicated disease models; (2) developing translational research that emphasizes rapid progress in disease model development and better translation from preclinical to clinical stages; (3) preventing AD through the development of robust methods and resources to advance trials and creating fundamental resources; and (4) innovating public/private partnerships and global collaborations.

The volume also includes a report that sets out to first estimate the consequent impact on the expected cost of developing disease-modifying treatments for AD and then to estimate the potential benefits of bringing together industry, academic, and government stakeholders to co-invest in, for example, developing better biomarkers and cognitive assessment tools, building out advanced registries and clinical trial-readiness cohorts, and establishing clinical trial platforms to investigate combinations of candidate drugs and biomarkers from the portfolios of multiple companies.

The third report presented in this volume explores nanomedicine, which is the application of nanotechnology to the discipline of medicine by using nanoscale materials for the diagnosis, monitoring, control, prevention, and treatment of disease. Nanomedicine holds tremendous promise to revolutionize medicine across disciplines and specialties, but this promise has yet to be fully realized. Beyond the typical complications associated with drug development, the fundamentally different and novel physical and chemical properties of some nanomaterials, compared to materials on a larger scale, can create a unique set of opportunities as well as safety concerns, which have only begun to be explored.

The last report included in this volume discusses the potential for adopting a critical load (CL) of air pollutant–deposition approach to inform natural resource protection and management in New York. The CL reflects the quantitative exposure to pollutants below which significant harmful effects on specified sensitive elements of the environment do not occur. The authors discuss how CLs can be used to protect sensitive ecosystems against the harmful effects of atmospheric sulfur and nitrogen deposition and associated soil and water acidification and nutrient enrichment. The CL can be used diagnostically to determine resources at risk and prescriptively to evaluate the effectiveness of regulations and to manage resources.